August 13, 2014
With the support of AFM Téléthon, Cure CMD and TREAT-NMD have developed a set of Standard Operating Procedures (SOPs) to study congenital muscular dystrophy (CMD) in mouse models. Deficiency in the LAMA2 gene (laminin, alpha 2) causes some of the most severe forms of muscular dystrophy. LAMA2 deficient mice are therefore valuable models to conduct research and gain better knowledge of the underlying causes of CMD. Furthermore, disease-specific animal models offer the opportunity to study the efficacy of new treatments for neuromuscular diseases. However, while there is no shortage of data on animal models, standard protocols to conduct research are essential to compare data generated by different research groups. Led by Dr. Raffaella Willmann, a number of researchers have contributed towards developing standardized study procedures. Several SOPs describing step-by-step protocols to conduct research on neuromuscular diseases are now available.
Access the available animal model SOPs from TREAT-NMD or from Cure CMD.
If you wish to contribute to SOP development, please email Anne Rutkowski at email@example.com